Neuland Laboratories (NSE:NEULANDLAB) Other Current Assets: ₹722 Mil (As of Mar. 2026)


NSE:NEULANDLAB Neuland Laboratories Ltd NSE:NEULANDLAB
92 GF Score
Price ₹18,956.00
GF Value ₹16,543.82
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Neuland Laboratories Other Current Assets?

Neuland Laboratories NSE:NEULANDLAB +0.06% 92 Other Current Assets is ₹722 Mil as of Mar. 2026. GuruFocus rates NSE:NEULANDLAB with a GF Score™ of 92/100 and a GF Value™ of ₹16,543.82 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Neuland Laboratories's other current assets for the quarter that ended in Mar. 2026 was ₹722 Mil.

Neuland Laboratories's quarterly other current assets declined from Sep. 2025 (₹971 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹722Mil).

Neuland Laboratories's annual other current assets declined from Mar. 2024 (₹850 Mil) to Mar. 2025 (₹774 Mil) declined from Mar. 2025 (₹774 Mil) to Mar. 2026 (₹722 Mil).


Neuland Laboratories Other Current Assets Related Terms


Neuland Laboratories Other Current Assets Historical Data

* Premium members only.

The historical data trend for Neuland Laboratories's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuland Laboratories Other Current Assets Chart

Neuland Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 656.35 643.78 850.38 773.61 721.86

Neuland Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 773.61 0.00 970.89 0.00 721.86
NSE:NEULANDLAB
92GF Score
Neuland Laboratories Ltd NSE:NEULANDLAB
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuland Laboratories Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of ₹722 Mil mean?
Neuland Laboratories (NSE:NEULANDLAB) has a Other Current Assets of ₹722 Mil as of Mar. 2026. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Neuland Laboratories.
Is Neuland Laboratories' Other Current Assets too high?
Neuland Laboratories' current Other Current Assets is ₹722 Mil. Overall, Neuland Laboratories has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' Other Current Assets compare to ZTS and UTHR?
Neuland Laboratories' Other Current Assets of ₹722 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Drug Manufacturers company?
A good Other Current Assets depends on the Drug Manufacturers industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Neuland Laboratories. Neuland Laboratories's current Other Current Assets is ₹722 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹16,543.82, compared to a current price of ₹18,956.00 — trading 14.6% above its estimated fair value. The current Other Current Assets is ₹722 Mil. Neuland Laboratories' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current Other Current Assets is ₹722 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued. The current stock price of ₹18,956.00 is trading 14.6% above its estimated GF Value™ of ₹16,543.82. GuruFocus considers Neuland Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:NEULANDLAB:

  • Other Current Assets: ₹722 Mil
  • GF Value™: ₹16,543.82 vs. price of ₹18,956.00 (14.6% above fair value)
  • GF Score™: 92/100 with 3 warning signs

No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Neuland Laboratories Business Description

Other Exchanges 524558:India
Address Road No. 82, Jubilee Hills, Plot No. 573A-III, Phoenix IVY Building, 11th Floor (5th Office Level), Hyderabad, TG, IND, 500033
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
92GF Score

Get the complete analysis for NSE:NEULANDLAB

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹18,956.00
Price
₹16,543.82
GF Value